A biomarker study for evaluating MN-166 in methamphetamine use disorder

Trial Profile

A biomarker study for evaluating MN-166 in methamphetamine use disorder

Planning
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Drug abuse
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 16 Nov 2017 New trial record
    • 09 Nov 2017 According to a MediciNova media release, this study has already completed FDA review and will be initiated by Dr. William Hoffman at Portland VA Medical Center and Oregon Health & Science University.
    • 09 Nov 2017 According to a MediciNova media release, this study is supported by the U.S. Department of Veterans Affairs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top